1. Academic Validation
  2. PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase

PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase

  • EMBO J. 2004 Aug 18;23(16):3303-13. doi: 10.1038/sj.emboj.7600345.
Frauke Leenders 1 Kristin Möpert Anett Schmiedeknecht Ansgar Santel Frank Czauderna Manuela Aleku Silke Penschuck Sibylle Dames Maria Sternberger Thomas Röhl Axel Wellmann Wolfgang Arnold Klaus Giese Jörg Kaufmann Anke Klippel
Affiliations

Affiliation

  • 1 atugen AG, Berlin, Germany.
Abstract

Chronic activation of the phosphoinositide 3-kinase (PI3K)/PTEN signal transduction pathway contributes to metastatic cell growth, but up to now effectors mediating this response are poorly defined. By simulating chronic activation of PI3K signaling experimentally, combined with three-dimensional (3D) culture conditions and gene expression profiling, we aimed to identify novel effectors that contribute to malignant cell growth. Using this approach we identified and validated PKN3, a barely characterized protein kinase C-related molecule, as a novel effector mediating malignant cell growth downstream of activated PI3K. PKN3 is required for invasive prostate cell growth as assessed by 3D Cell Culture assays and in an orthotopic mouse tumor model by inducible expression of short hairpin RNA (shRNA). We demonstrate that PKN3 is regulated by PI3K at both the expression level and the catalytic activity level. Therefore, PKN3 might represent a preferred target for therapeutic intervention in cancers that lack tumor suppressor PTEN function or depend on chronic activation of PI3K.

Figures